Literature DB >> 33587136

Projected Estimates of Opioid Mortality After Community-Level Interventions.

Benjamin P Linas1,2, Alexandra Savinkina1, R W M A Madushani1, Jianing Wang1, Golnaz Eftekhari Yazdi1, Avik Chatterjee3,4, Alexander Y Walley3,4, Jake R Morgan5, Rachel L Epstein1,2, Sabrina A Assoumou1,2, Sean M Murphy5,6, Bruce R Schackman5,6, Stavroula A Chrysanthopoulou7, Laura F White5, Joshua A Barocas1,2.   

Abstract

Importance: The United States is experiencing a crisis of opioid overdose. In response, the US Department of Health and Human Services has defined a goal to reduce overdose mortality by 40% by 2022. Objective: To identify specific combinations of 3 interventions (initiating more people to medications for opioid use disorder [MOUD], increasing 6-month retention with MOUD, and increasing naloxone distribution) associated with at least a 40% reduction in opioid overdose in simulated populations. Design, Setting, and Participants: This decision analytical model used a dynamic population-level state-transition model to project outcomes over a 2-year horizon. Each intervention scenario was compared with the counterfactual of no intervention in simulated urban and rural communities in Massachusetts. Simulation modeling was used to determine the associations of community-level interventions with opioid overdose rates. The 3 examined interventions were initiation of more people to MOUD, increasing individuals' retention with MOUD, and increasing distribution of naloxone. Data were analyzed from July to November 2020. Main Outcomes and Measures: Reduction in overdose mortality, medication treatment capacity needs, and naloxone needs.
Results: No single intervention was associated with a 40% reduction in overdose mortality in the simulated communities. Reaching this goal required use of MOUD and naloxone. Achieving a 40% reduction required that 10% to 15% of the estimated OUD population not already receiving MOUD initiate MOUD every month, with 45% to 60%% retention for at least 6 months, and increased naloxone distribution. In all feasible settings and scenarios, attaining a 40% reduction in overdose mortality required that in every month, at least 10% of the population with OUD who were not currently receiving treatment initiate an MOUD. Conclusions and Relevance: In this modeling study, only communities with increased capacity for treating with MOUD and increased MOUD retention experienced a 40% decrease in overdose mortality. These findings could provide a framework for developing community-level interventions to reduce opioid overdose death.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33587136      PMCID: PMC7885041          DOI: 10.1001/jamanetworkopen.2020.37259

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  32 in total

1.  Distance traveled to outpatient drug treatment and client retention.

Authors:  Kyle Beardsley; Eric D Wish; Dawn Bonanno Fitzelle; Kevin O'Grady; Amelia M Arria
Journal:  J Subst Abuse Treat       Date:  2003-12

2.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

3.  Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.

Authors:  Michael A Irvine; Jane A Buxton; Michael Otterstatter; Robert Balshaw; Reka Gustafson; Mark Tyndall; Perry Kendall; Thomas Kerr; Mark Gilbert; Daniel Coombs
Journal:  Lancet Public Health       Date:  2018-04-18

4.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.

Authors:  Jake R Morgan; Bruce R Schackman; Jared A Leff; Benjamin P Linas; Alexander Y Walley
Journal:  J Subst Abuse Treat       Date:  2017-07-03

5.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

6.  Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users.

Authors:  B Nosyk; L Li; E Evans; D Huang; J Min; T Kerr; M L Brecht; Y I Hser
Journal:  Drug Alcohol Depend       Date:  2014-04-08       Impact factor: 4.492

7.  Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.

Authors:  Elenore Patterson Bhatraju; Ellie Grossman; Babak Tofighi; Jennifer McNeely; Danae DiRocco; Mara Flannery; Ann Garment; Keith Goldfeld; Marc N Gourevitch; Joshua D Lee
Journal:  Addict Sci Clin Pract       Date:  2017-02-28

8.  Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.

Authors:  Rebecca L Haffajee; Lewei Allison Lin; Amy S B Bohnert; Jason E Goldstick
Journal:  JAMA Netw Open       Date:  2019-06-05

9.  Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.

Authors:  William C Goedel; Aaron Shapiro; Magdalena Cerdá; Jennifer W Tsai; Scott E Hadland; Brandon D L Marshall
Journal:  JAMA Netw Open       Date:  2020-04-01

10.  Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison.

Authors:  Sheila M Bird; Andrew McAuley; Samantha Perry; Carole Hunter
Journal:  Addiction       Date:  2016-02-04       Impact factor: 6.526

View more
  10 in total

1.  Simulating the impact of Addiction Consult Services in the context of drug supply contamination, hospitalizations, and drug-related mortality.

Authors:  Caroline A King; Ryan Cook; Haven Wheelock; P Todd Korthuis; Judith M Leahy; Amelia Goff; Cynthia D Morris; Honora Englander
Journal:  Int J Drug Policy       Date:  2021-11-24

2.  Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.

Authors:  Xiao Zang; Alexandria Macmadu; Maxwell S Krieger; Czarina N Behrends; Traci C Green; Jake R Morgan; Sean M Murphy; Shayla Nolen; Alexander Y Walley; Bruce R Schackman; Brandon Dl Marshall
Journal:  Int J Drug Policy       Date:  2021-09-03

3.  Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.

Authors:  Alexandra Savinkina; Rajapaksha W M A Madushani; Golnaz Eftekhari Yazdi; Jianing Wang; Joshua A Barocas; Jake R Morgan; Sabrina A Assoumou; Alexander Y Walley; Benjamin P Linas; Sean M Murphy
Journal:  Addiction       Date:  2022-04-12       Impact factor: 7.256

4.  Modeling the evolution of the US opioid crisis for national policy development.

Authors:  Tse Yang Lim; Erin J Stringfellow; Celia A Stafford; Catherine DiGennaro; Jack B Homer; Wayne Wakeland; Sara L Eggers; Reza Kazemi; Lukas Glos; Emily G Ewing; Calvin B Bannister; Keith Humphreys; Douglas C Throckmorton; Mohammad S Jalali
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-31       Impact factor: 12.779

5.  Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

Authors:  Jake R Morgan; Alexander Y Walley; Sean M Murphy; Avik Chatterjee; Scott E Hadland; Joshua Barocas; Benjamin P Linas; Sabrina A Assoumou
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852

6.  Prescribing Naloxone to High-Risk Patients in the Emergency Department: Is it Enough?

Authors:  Scott G Weiner; Jason A Hoppe
Journal:  Jt Comm J Qual Patient Saf       Date:  2021-04-04

7.  Harm reduction in the Heartland: public knowledge and beliefs about naloxone in Nebraska, USA.

Authors:  Allison Schlosser; Patrick Habecker; Rick Bevins
Journal:  Harm Reduct J       Date:  2022-03-04

Review 8.  Data needs and models for the opioid epidemic.

Authors:  Carlos Blanco; Melanie M Wall; Mark Olfson
Journal:  Mol Psychiatry       Date:  2021-10-29       Impact factor: 13.437

9.  Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018.

Authors:  Evan D Peet; David Powell; Rosalie Liccardo Pacula
Journal:  JAMA Health Forum       Date:  2022-08-05

10.  Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis.

Authors:  Erin J Stringfellow; Tse Yang Lim; Keith Humphreys; Catherine DiGennaro; Celia Stafford; Elizabeth Beaulieu; Jack Homer; Wayne Wakeland; Benjamin Bearnot; R Kathryn McHugh; John Kelly; Lukas Glos; Sara L Eggers; Reza Kazemi; Mohammad S Jalali
Journal:  Sci Adv       Date:  2022-06-24       Impact factor: 14.957

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.